Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Choueiri, Toni K; Regan, Meredith M; Rosenberg, Jonathan E; Oh, William K; Clement, Jessica; Amato, Angela M; McDermott, David; Cho, Daniel C; Atkins, Michael B; Signoretti, Sabina. (2010). BJU international, 6, (106), 772-8.
Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.
Choueiri, Toni K; Duh, Mei Sheng; Clement, Jessica; Brick, Ashley J; Rogers, Miranda J; Kwabi, Christabel; Shah, Karishma; Percy, Andrew G; Antràs, Lucia; Jayawant, Sujata S; Chen, Kristina; Wang, Si-Tien; Luka, Andi; Neary, Maureen P; McDermott, David; Oh, William K. (2010). BJU international, 9, (105), 1247-54.
The high-dose aldesleukin (IL-2) "select" trial: a trial designed to prospectively validate predictive models of response to high-dose IL-2 treatment in patients with metastatic renal cell carcinoma.
Clement, Jessica M; McDermott, David F. (2009). Clinical genitourinary cancer, 2, (7), E7-9.
Prostasol and venous thromboembolism.
Clement, Jessica; Bubley, Glenn. (2008). Urology, 3, (72), 664-6.
A 51-year-old woman with shortness of breath and edema.
Desai, Sonali; Clement, Jessica; Landaw, Stephen. (2008). Arthritis and rheumatism, 8, (59), 1184-90.
Treatment Discontinuations, Dose Reductions and Interruptions for Angiogenesis Inhibitor Therapies in Patients with Metastatic Renal Cell Carcinoma (mRCC).
A.J. Brick, D.F. McDermott, J.M. Clement, C. Kwabi, K. Shah, J.R. Weiner, M.S. Duh, M.P. Neary, W.K. Oh, T.K. Choueiri. Supplement to Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings, 15S, (26), 638s.
Detecting Disparities in Long-Term Prostate Cancer (PCa) Survival with Dependent-Censoring.
Clement, J.M., Li, Y., Othus, M., Bubley, G. ASCO Genitourinary Cancers Symposium Abstract Number: 20,
Patients with Metastatic Renal Cell Carcinoma (mRCC) Receiving Sunitinib in “Real-World” Clinical Practice: Baseline Characteristics and Treatment Efficacy.
J.M. Clement, D.F. McDermott, T.K. Choueiri, A.J. Brick, C. Kwabi, K. Shah, J.R. Weiner, M.S. Duh, M.P. Neary, W.K. Oh. Supplement to Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings, 15S, (26), 676s.
Patients with Metastatic Renal Cell Carcinoma Receiving Angiogenesis Inhibitor Therapies: Treatment Efficacy and Safety in Clinical Practice.
McDermott, D., Choueiri, T.K., Clement, J., Brick, A.J., Kwabi, C., Shah, K., Banerjee, A., Duh, M.S., Neary, M., Oh, W.K. European Society for Medical Oncology Congress Abstract Number: 488,
Difference of opinion.
Reis, Leonardo de Oliveira; Carter, H Ballentine. International braz j urol : official journal of the Brazilian Society of Urology, 1, (41), 10-4.
Carbonic Anhydrase IX (CA IX) and Pathologic Features as Predictors of Outcome in Patients with Metastatic Renal Cell Carcinoma (mRCC) Receiving VEGF-Targeted Therapy.
T.K. Choueiri, M.M. Regan, A.J. Brick, J.M. Clement, C. Kwabi, K. Shah, A. Amato, D.F. McDermott, M.B. Atkins, S. Signoretti. Journal of Clinical Oncology: 2008 ASCO Annual Meeting Proceedings, 15S, (26), 674s.